Moderna, Inc.

NASDAQ Global Select
Back to all articles
Very Bullish +85

Moderna Stock Surges 9% on mRNA Cancer Vaccine… | Pomegra Briefs

AI-generated analysis

📈 Moderna stock surged 9% to $149 following a Phase 3 win for its personalized mRNA cancer vaccine with Merck.

💉 The intismeran autogene (mRNA-4157) trial showed reduced melanoma recurrence risk compared to Keytruda alone in 1,137 patients.

✅ FDA approved mFLUSIVA as the first mRNA flu vaccine in the U.S. on August 5.

✅ Updated COVID-19 vaccines received FDA approval on August 27 for the 2026-2027 period.

🚀 Moderna stock has rallied from $29 to nearly $150, marking a major 2026 turnaround story.

🔬 The personalized cancer vaccine represents the first of its kind to reach patients, targeting a multi-billion dollar market.

📈 Argus Research upgraded MRNA to Buy with an $180 price target following recent catalysts.

🗣️ Investors are positioning ahead of Moderna's presentation at the Morgan Stanley Global Healthcare Conference on September 14.

Bullish Signals
  • Moderna stock surged 9% to $149 driven by a Phase 3 win where its personalized cancer vaccine significantly reduced melanoma recurrence risk compared to Keytruda alone.
  • The FDA approved mFLUSIVA, the first mRNA flu vaccine in the U.S., and updated COVID-19 vaccines, proving regulatory success beyond the original pandemic business.
  • Argus Research upgraded MRNA to a Buy rating with an $180 price target, reflecting strong investor confidence in the company's recent clinical and regulatory milestones.
  • The personalized cancer vaccine technology is custom-built from patient tumor mutations, opening a potential new era in cancer treatment worth billions annually.
Full Analysis
Moderna stock surged approximately 9% on Friday, reaching a price of $149, driven primarily by a significant Phase 3 clinical trial win for its personalized mRNA cancer vaccine in partnership with Merck. The trial demonstrated that the vaccine, known as intismeran autogene (mRNA-4157), significantly reduced melanoma recurrence risk compared to Keytruda used alone in a study involving 1,137 patients. This breakthrough positions Moderna at the forefront of a potential new era in cancer treatment, with the technology capable of being custom-built from individual patient tumor mutations. Beyond the oncology success, Moderna secured regulatory momentum with two recent FDA approvals: mFLUSIVA, the first mRNA flu vaccine cleared in the United States on August 5, and updated COVID-19 vaccines approved on August 27. These approvals validate Moderna's ability to win regulatory battles beyond its original pandemic-focused business model, diversifying its revenue streams into seasonal flu and ongoing respiratory health markets. The stock has executed a dramatic turnaround in 2026, rising from roughly $29 at the start of the year to nearly $150. Analysts are reacting positively to these developments, with Argus Research upgrading MRNA to a Buy rating and setting an $180 price target. Investors are currently positioning ahead of Moderna's upcoming presentation at the Morgan Stanley Global Healthcare Conference scheduled for September 14.